Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification

<i>Mycobacterium tuberculosis</i>, the pathogen that causes tuberculosis, is responsible for the death of 1.5 million people each year and the number of bacteria resistant to the standard regimen is constantly increasing. This highlights the need to discover molecules that act on new <...

Full description

Saved in:
Bibliographic Details
Main Authors: Léo Faïon (Author), Kamel Djaout (Author), Catalin Pintiala (Author), Catherine Piveteau (Author), Florence Leroux (Author), Alexandre Biela (Author), Stéphanie Slupek (Author), Rudy Antoine (Author), Monika Záhorszká (Author), Francois-Xavier Cantrelle (Author), Xavier Hanoulle (Author), Jana Korduláková (Author), Benoit Deprez (Author), Nicolas Willand (Author), Alain R. Baulard (Author), Marion Flipo (Author)
Format: Book
Published: MDPI AG, 2023-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8f8af7ff2c8049dca93bfab59dd0da06
042 |a dc 
100 1 0 |a Léo Faïon  |e author 
700 1 0 |a Kamel Djaout  |e author 
700 1 0 |a Catalin Pintiala  |e author 
700 1 0 |a Catherine Piveteau  |e author 
700 1 0 |a Florence Leroux  |e author 
700 1 0 |a Alexandre Biela  |e author 
700 1 0 |a Stéphanie Slupek  |e author 
700 1 0 |a Rudy Antoine  |e author 
700 1 0 |a Monika Záhorszká  |e author 
700 1 0 |a Francois-Xavier Cantrelle  |e author 
700 1 0 |a Xavier Hanoulle  |e author 
700 1 0 |a Jana Korduláková  |e author 
700 1 0 |a Benoit Deprez  |e author 
700 1 0 |a Nicolas Willand  |e author 
700 1 0 |a Alain R. Baulard  |e author 
700 1 0 |a Marion Flipo  |e author 
245 0 0 |a Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification 
260 |b MDPI AG,   |c 2023-02-01T00:00:00Z. 
500 |a 10.3390/ph16030335 
500 |a 1424-8247 
520 |a <i>Mycobacterium tuberculosis</i>, the pathogen that causes tuberculosis, is responsible for the death of 1.5 million people each year and the number of bacteria resistant to the standard regimen is constantly increasing. This highlights the need to discover molecules that act on new <i>M. tuberculosis</i> targets. Mycolic acids, which are very long-chain fatty acids essential for <i>M. tuberculosis</i> viability, are synthesized by two types of fatty acid synthase (FAS) systems. MabA (FabG1) is an essential enzyme belonging to the FAS-II cycle. We have recently reported the discovery of anthranilic acids as MabA inhibitors. Here, the structure-activity relationships around the anthranilic acid core, the binding of a fluorinated analog to MabA by NMR experiments, the physico-chemical properties and the antimycobacterial activity of these inhibitors were explored. Further investigation of the mechanism of action <i>in bacterio</i> showed that these compounds affect other targets than MabA in mycobacterial cells and that their antituberculous activity is due to the carboxylic acid moiety which induces intrabacterial acidification. 
546 |a EN 
690 |a MabA inhibitors 
690 |a anthranilic acid 
690 |a FabG1 
690 |a tuberculosis 
690 |a mycolic acids 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 16, Iss 3, p 335 (2023) 
787 0 |n https://www.mdpi.com/1424-8247/16/3/335 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/8f8af7ff2c8049dca93bfab59dd0da06  |z Connect to this object online.